Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not mainly eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011. It is grouped under the following drug class(es): DPP-4 inhibitors and Hypoglycemics. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Linagliptina, Tradjenta and Trajenta. Its PubChem CID is 10096344.

CAS No 668270-12-0
Molecular Formula C25H28N8O2
Molecular Weight 472.50 g/mol
Synonyms 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione

Frequently Asked Questions